Badanie skuteczności i bezpieczeństwa kremu z ruksolitynibem u dorosłych z przewlekłym wypryskiem rąk

Chronic Hand Eczema is a skin condition that causes redness, itching, and sometimes blisters on the hands. This study is looking at how well a cream called ruxolitinib works for people with moderate to severe forms of this condition. The cream is applied to the skin and contains an active ingredient that may help reduce symptoms. The study will compare the effects of ruxolitinib cream with a cream that looks the same but does not contain the active ingredient, known as a placebo.

The main goal of the study is to see if ruxolitinib cream can improve the symptoms of Chronic Hand Eczema over a period of 16 weeks. Participants will be randomly assigned to use either the ruxolitinib cream or the placebo cream. The study is designed to be "double-blind," meaning neither the participants nor the researchers will know who is using which cream during the initial phase. After this period, all participants will have the chance to use the ruxolitinib cream in an open-label extension, where everyone knows they are using the active cream.

The study will monitor changes in the severity of eczema symptoms, such as itching and skin pain, and will also look at the overall quality of life for participants. The study will last for a total of 32 weeks, including the initial 16-week period and the open-label extension. Participants will have regular check-ups to assess their progress and any side effects they might experience. The results will help determine the effectiveness and safety of ruxolitinib cream for treating Chronic Hand Eczema.